[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie… - The Lancet …, 2021 - Elsevier
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
[引用][C] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational …
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - produccioncientifica.ucm.es
Background: The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - europepmc.org
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …